ABOUT

ScinoPharm Taiwan

For every life. With every trust.

ScinoPharm Taiwan is a professional pharmaceutical company specializing in high-barrier API and drug product development and manufacturing, dedicated to providing fully integrated solutions as a trusted strategic partner for global clients.

Established in 1997 and headquartered in the Tainan Science Park, ScinoPharm Taiwan operates advanced, FDA- and cGMP-compliant facilities with automated production systems. As an important member of the global pharmaceutical community, ScinoPharm possesses strong R&D and high-standard manufacturing capabilities, maintaining technological leadership and diverse products in the oncology field.

Global Partnerships with Leading Pharmaceutical Companies.

ScinoPharm collaborates with top-tier patented and generic pharmaceutical companies worldwide, including several of the world's top ten. Our expertise spans CNS, cardiovascular, and orphan drug development, supported by an FDA-approved sterile injectable facility that enables a seamless, one-stop solution from API to drug product. With three zero-deficiency FDA inspections, we demonstrate our commitment to world-class quality and regulatory excellence.

In addition to API and drug product development and manufacturing, ScinoPharm offers flexible and efficient CDMO services—from process development and clinical sample preparation to commercial-scale production—tailored to accelerate our partners' innovations to market. Our technology platforms encompass both small molecules and peptides, delivering integrated, reliable, and value-driven solutions to our global partners.

SCINOPHARM

MISSION

Brand Mission

We apply our expertise with rigorous standards and continuous improvement to deliver safe, effective, and high-quality medicines.

CORE

VALUE

Core Value

Integrity at our core

We act with transparency, honesty, and accountability to build trust and ensure every product meets the highest standards.

Scientific expertise

We leverage our deep technical knowledge to deliver scientifically proven solutions for the global pharmaceutical industry.

Forward Innovation

We challenge conventions and advance technologies to create new possibilities in healthcare.

Commitment to life

We safeguard life through unwavering dedication to quality, safety, and human well-being.

0 +

Exported Countries

0 +

Countries with Official GMP Approval

Globally Registered DMFs

GMP Inspections Passed
(2001–2024)

MILESTONE

2025

Jul.
Compounding room established and operational
Oct.
New brand identity officially established and launched

2024

Jan.
Carried out ISO 14067 third-party verification of a carbon footprint inventory for one of target products
Mar.
The injectable plant passed the third U.S. FDA site inspection
Nov.
ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection
Dec.
Completed GHG Protocol third-party verification of greenhouse gas emissions (Scope 1-3) in 2023

2023

Sep.
Completed ISO 14064-1 third-party verification of greenhouse gas emission in 2022

2022

May
Passed the eighth U.S. FDA site inspection in Taiwan, and injectable plant passed the first U.S. FDA site inspection
May
Adopted the ISO 14064-1 Greenhouse Gas Inventory in 2022 to facilitate planning
Nov.
New warehouse building on Taiwan site
Dec.
Passed the ninth U.S. FDA site inspection in Taiwan, and injectable plant passed the second U.S. FDA site inspection

2021

Apr.
ScinoPharm Injectable Plant received the first GMP inspection by Taiwan Food and Drug Administration(TFDA)
Dec.
The new manufacturing facility of the injectable plant at ScinoPharm passed GMP/GDP on-site inspection approved by Taiwan Food and Drug Administration (TFDA)

2020

Sep.
SciAnda (Changshu) Pharmaceutical Ltd. had its first China National Medical Products Administration (NMPA) on-site inspection of drug registration and GMP compliance inspection

2019

May
Passed the seventh U.S. FDA site inspection in Taiwan
Dec.
Developed by ScinoPharm and sold by Baxter, an injectable formulation of adjuvant antiemetic drugs for chemotherapy patients was launched

2018

May
SciAnda (Changshu) Pharmaceutical Ltd. passed the first Japanese PMDA site inspections
Nov.
The first injectable oncology product was launched in the U.S. market which was the result of our joint venture with SAGENT Pharmaceuticals

2017

Feb.
Passed the sixth U.S. FDA site inspection in Taiwan
Sep.
Passed the second Japan Pharmaceuticals and Medical Devices Agency (PMDA) site inspection in Taiwan

2016

Oct.
Passed the first European Directorate for the Quality of Medicine & HealthCare (EDQM) site inspection in Taiwan

2015

Mar.
Passed the fifth U.S. FDA site inspection in Taiwan
Oct.
SciAnda (Changshu) Pharmaceutical Ltd. passed U.S. FDA inspection

2014

Aug.
SciAnda (Changshu) Pharmaceutical Ltd. passed Mexican healthy authority (COFEPRIS) inspection

2013

Jul.
Groundbreaking ceremony for new sterile injectable plant facility, constructed as part of ScinoPharm's vertical integration strategy
Aug.
Passed the first European Medicine Agency (EMA) site inspection in Taiwan
Nov.
Official inauguration of SciAnda (Changshu) Pharmaceutical Ltd. facility after Phase II construction was completed

2012

Aug.
Passed the fourth U.S. FDA plant inspection
Nov.
Selected as one of the constituent stocks of the Morgan Stanley Capital International (MSCI) Taiwan Index, the first biotech company in Taiwan elected
Dec.
43 DMFs were registered with the FDA in the United States, and a total of 631 DMFs were registered worldwide

2011

Sep.
Publicly listed on the Taiwan Stock Exchange Corporation (TWSE), stock code 1789

2010

Aug.
Signed an investment cooperation pact with Tanvex Biologics, a US company, and Ruentex Group, to jointly develop Biosimilars
Oct.
Listed as an Emerging Stock on the Taipei Exchange, stock code 1789
Nov.
Became the first biotechnology pharmaceutical company to be certified as an Authorized Economic Operator (AEO) by the Taiwan Ministry of Finance

2009

Aug.
Investment and establishment of SciAnda (Changshu) Pharmaceutical Ltd.

2008

Jun.
Passed the plant inspection conducted by Hungarian (NIP), an EU member state
Jun.
Passed Japan Pharmaceuticals and Medical Devices Agency (PMDA) plant inspection
Sep.
Passed Korean FDA (KFDA) plant inspection
Oct.
Passed third U.S. FDA plant inspection
Dec.
New and lagger quality control building commenced operations
Dec.
Revenue surpassed USD 100 million

2007

May
Expansion of production line was completed, including Kilo II and ESP II
Oct.
Passed Australian TGA plant inspection

2005

Aug.
passed second U.S. FDA plant inspection

2002

Nov.
Inauguration of main manufacturing building on Taiwan site

2001

Jan.
The first Drug Master File (Drug Master File, DMF) submitted to FDA
Feb.
Establishment of the reinvested ScinoPharm (Kunshan) Biotech Ltd.
May
Our customer submitted to the abbreviated new drug application (ANDA) for generic drugs to U.S. FDA, being the first one to use the company's active pharmaceutical ingredient (API) Establishment of the reinvested ScinoPharm Biotech Ltd.
Jun.
Small manufacturing plant (SMU) begins operations
Oct.
Passed first U.S. FDA plant inspection

2000

Jan.
Kilo Lab begins operations
Mar.
The first batch of Good Manufacturing Practices (Good Manufacturing Practices, GMP) products delivered to clients
May
Pilot Plant begins operations
Nov.
Mini Plant begins operations

1999

Oct.
Relocated into the laboratories and offices in Southern Taiwan Science Park

1998

May
The US Food and Drug Administration (FDA) screened the company's plant layout design and validation plan
May
Groundbreaking ceremony held at the current site of Southern Taiwan Science Park

1997

Nov.
ScinoPharm Taiwan, Ltd. established

AWARDS

Award Glory

2025

Oct.
Awarded the 2025 "Excellence in Corporate Social Responsibility Award" issued by CommonWealth Magazine

2024

Sep.
Awarded the 2024 "Excellence in Corporate Social Responsibility Award" issued by CommonWealth Magazine
Oct.
Awarded 21st Century Foundation "Net-Zero Industry Competitiveness" Excellence Award
Nov.
Awarded Business Weekly 2024 "Top 100 Carbon Competitiveness"

2023

Nov.
Awarded the bronze medal of 16th ARTS & BUSINESS AWARDS by Taiwan Ministry of Culture

2021

May
Recognized as Best Pharmaceutical R&D & Manufacturing Company – Asia by 《Acquisition International》
May
Recognized as Top CMOs IN APAC 2021 by《Pharma Tech Outlook》
Dec.
Awarded the bronze medal of 15th ARTS & BUSINESS AWARDS by Taiwan Ministry of Culture

2019

Nov.
Received the Authorized Economic Operator Accreditation
Dec.
Granted the Excellence in Workplace Health and Safety Award

2018

May
Rated top 5% in the 4th "Corporate Governance Evaluation" by Taiwan Stock Exchange Corporation
Aug.
Awarded the 2017 "CSR Corporate Citizenship Award" by CommonWealth Magazine

2017

Jul.
Awarded the Company of the Year in the 105th import/export performance by Bureau of Foreign Trade, Ministry of Economic Affairs
Aug.
Awarded the 2016 "CSR Corporate Citizenship Award" by CommonWealth Magazine
Dec.
Awarded second prize in the "Best Investor Relations Service in the Greater China Region" category in the biotechnology industry by IR Magazine, a global investor relations magazine for professionals

2016

Jun.
Rated top 5% in the 2nd "Corporate Governance Evaluation" by Taiwan Stock Exchange Corporation
Jul.
Awarded the 2016 Taiwan API Manufacturing Company of the Year by Frost & Sullivan
Nov.
Awarded the 2016 Excellence in Workplace Health and Safety Award issued by Southern Taiwan Science Park
Dec.
Received three Authorized Economic Operators (AEO) certification by Customs Administration, Ministry of Finance

2015

Apr.
Rated A++ for two consecutive years in the "Information Disclosure and Transparency" Ranking results by Taiwan Stock Exchange Corporation
Jun.
Awarded 4th "National Industrial Innovation Award" by the Ministry of Economic Affairs
Jun.
Rated top 5% in the first "Corporate Governance Evaluation" by Taiwan Stock Exchange Corporation
Jul.
Awarded the Company of the Year in the 103rd import/export performance by Bureau of Foreign Trade, Ministry of Economic Affairs
Aug.
Awarded the "Citizenship Award" for "Top 100 CSR" by CommonWealth Magazine

2014

Jun.
Rated A++ in the 11th Information Disclosure and Transparency Ranking results by Taiwan Stock Exchange Corporation
Oct.
Ranked as the top Taiwan biotech pharmaceutical corporation in CommonWealth Magazine's Benchmark Enterprise survey for two consecutive years
Oct.
Recognized as one of Most Honored Companies in Asia by the authoritative financial magazine "Institutional Investor"; the only Taiwanese biotech company to receive such an award

2013

Jan.
Ranked as one of 79 A+ corporations in Taiwan by Global Views Monthly
Sep.
Awarded "102nd National Invention and Creation Award" by the Intellectual Property Office, Taiwan Ministry of Economic Affairs
Oct.
Ranked as the top Taiwan biotech pharmaceutical corporation in CommonWealth Magazine's Benchmark Enterprise survey
Dec.
Recognized as an Authorized Economic Operator (AEO) by the Taiwan Ministry of Finance

2012

Jul.
Awarded "Outstanding Bio Industry Golden Award" by the Bio Taiwan Industry Organization
Aug.
Ranked as the number two Taiwan biotech pharmaceutical corporation in CommonWealth Magazine's Benchmark Enterprise survey
Nov.
Received management systems accreditation by the Taiwan Responsible Care Association (TRCA) in six categories for the second time, including process safety, employee safety, product safety, and emergency response

2011

Nov.
Received "Top 100 Innovation Award" by the Industrial Development Bureau, Taiwan Ministry of Economic Affairs

2010

Aug.
Received a 5-year "Taiwan Occupational Safety and Hygiene Management System" (TOSHMS) performance accreditation from the Council of Labor Affairs
Sep.
Awarded "Industry Contribution Award" by the Taiwan Chemical Industry Association
Sep.
Recognized as an Authorized Economic Operator (AEO) by the Taiwan Ministry of Finance

2009

Sep.
Became first API plant in Asia to receive "High-Potency Synthetic Pharmaceutical Safety certificate" from SafeBridge, an international biotechnology and pharmaceutical occupational safety and hygiene accreditation company
Nov.
Awarded "Outstanding Enterprise Innovation Award" at the Ministry of Economic Affairs’ 17th Annual Industrial Technology Advancement Award ceremony
Nov.
Received management systems accreditation by the "Taiwan Responsible Care Association" (TRCA) in six categories, including process safety, employee safety, product safety, and emergency response
Dec.
Awarded "Drug Research and Development Science and Technology Golden Award" by the Taiwan Executive Yuan's Department of Health for six products including Docetaxel, Galantamine, and Irinotecan

2008

Sep.
Awarded "Outstanding Contribution to Industrial Safety and Hygiene Award" by the Southern Taiwan Science Park Administration

ORGANIZATION

Organization

Chih-Hsien Lo

Chairman and General Chief Strategy Officer

Experience Chairman, Uni-President Enterprises Corp.
Education MBA from the University of California, Los Angeles, USA

Li-An(Susan) Lu

President and CEO

Experience Over 20 years of experience in financial operations and corporate investment management at Uni-President Enterprises Corp.
Education M.S. in Finance, National Sun Yat-sen University
B.S. in Agricultural Economics, National Taiwan University

LH Lien

Vice-President of Marketing & Sales and Operations

Experience Over 20 years of comprehensive experience in R&D, production, and sales within the pharmaceutical industry
Education M.S. in Chemical Engineering from National Cheng Kung University

Gloria Chang

Vice President of R&D Division and Chief Scientific Officer

Experience Over 20 years of experience in the pharmaceutical industry Held positions in Quality Control, Analytical R&D, Biotech, Peptide Product Development, Pharmaceutical Development, and Head of Quality Management Division
Education Ph.D. degree in Chemistry from National Taiwan University

Katy Cheng

Vice President of Quality Management

Experience Over 30 years of experience in drug product quality and production management
Education M.S. in Business Administration, National Chiao-Tung University
B.S. in Pharmacy, Kaohsiung Medical University

調整en